ArticleArthroplasty today2026
Bone Morphogenetic Protein Augmentation of Large Acetabular Defects in Revision Total Hip Arthroplasty: A Viable Option for Massive Bone Loss.
Article in Arthroplasty today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large acetabular defects in revision total hip arthroplasty (THA) are challenging surgical problems. While bone morphogenetic proteins (BMPs) have shown promise in enhancing bone growth, the long-term outcomes of revision THA with BMP-2 augmentation for large acetabular defects are unknown. Methods: A single-surgeon retrospective cohort study of consecutive patients who received BMP-2 augmentation during revision THA was conducted. Acetabular defects were graded using the Paprosky classification, heterotopic ossification was quantified using the Brooker classification, and bone consolidation was assessed radiographically. Postoperative complications, subsequent reoperations, and Oxford Hip Scores were recorded. Kaplan-Meier survival estimates were generated with all-cause reoperation as the endpoint. Results: Fifteen patients (18 hips) with an average age of 64.6 ± 16.1 years and a mean follow-up of 76.3 ± 43.1 months were included. Patients underwent an average of 1.9 ± 1.3 surgeries prior to revision. There were 10 hips with Paprosky 3B defects, 3 with 3A defects, 3 with 2C defects, and 2 with 2B defects. Eleven hips had pelvic discontinuity. Postoperatively, 15 hips (83.3%) showed radiographic evidence of >50% bone consolidation. With all-cause reoperation as the primary endpoint, 6- and 10-year survivorship was 90.0% (95% CI: 47.3%-100.0%) and 70.0% (95% CI: 32.9%-89.2%), respectively. Regarding acetabular loosening, both 6- and 10-year survivorship was 90.0% (95% CI: 47.3%-98.5%). Mean Oxford Hip Score was 34.8 ± 9.2 at final follow-up. Discussion: BMP-2 augmentation is a viable treatment option in revision THA when massive bone loss is encountered. However, further research is necessary to elucidate the safety and efficacy of BMP-2 adjuvant therapy in the setting of revision THA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.